CoChat
Sign Up
Cited by 38Endometrial and Cervical Cancer TreatmentsCervical Cancer and HPV ResearchHead and Neck Cancer Studies

The DOI matches its Crossref record.

Chemoradiation for Carcinoma of the Cervix: Advances and Opportunities

Eifel, Patricia J.·2000·Radiation Research
DOI 10.1667/0033-7587(2000)154[0229:cfcotc]2.0.co;2
Open this paper in CoChat — free account

Abstract

Although it is possible to cure many patients with locally advanced cervical cancer using radiation therapy alone, loco-regional relapse continues to be a component of most recurrences. To improve control rates, clinicians have investigated ways of combining chemotherapy and radiation for more than 30 years. Despite encouraging results from phase II trials of neoadjuvant chemotherapy, randomized trials failed to improve on the results with radiation therapy alone. For a number of reasons, early trials of concurrent chemoradiation were inconclusive. However, recent reports of five large prospective randomized trials demonstrated dramatic improvements in survival and local control rates when cisplatin-containing chemotherapy was given during radiation therapy. These results also suggest a number of avenues for future research.

Overview

Integrity signals

Registry

Crossref · 10.1667/0033-7587(2000)154[0229:cfcotc]2.0.co;2

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • DNA damaging therapy utilizing chemotherapeutics such as cisplatin, paclitaxel, gemcitabine, topotecan, 5-fluorouracil, or MMC, combined with radiotherapy, has produced improved survival outcomes for late-stage CC.

    “Over recent decades, DNA damaging therapy utilizing chemotherapeutics such as cisplatin, paclitaxel, gemcitabine, topotecan, 5-fluorouracil, or mitomycin C (MMC), combined with radiotherapy, has produced improved survival outcomes for late-stage CC [2].”

    From Combining Mitomycin C with inhibition of BAD phosphorylation enhances apoptotic cell death in advanced cervical cancer (2024) · cites this paper as [2]

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 45

  1. 10.1056/NEJM199904153401501 · DOI
  2. 10.1006/gyno.1998.5330 · DOI
  3. 10.1056/NEJM199904153401502 · DOI
  4. 10.1056/NEJM199904153401503 · DOI
  5. C. W. Whitney, W. Sause, B. N. Bundy, J. H. Malfetano, E. B. Hannigan, W. C. Fowler, D. L. Clarke-Pearson, and S-Y. Liao .A randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB–IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study., J. Clin. Oncol, 17 :1339 –1348 .1999 . · DOI
  6. P. J. Eifel, M. Morris, J. T. Wharton, and M. J. Oswald .The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix., Int. J. Radiat. Oncol. Biol. Phys, 29 :9 –16 .1994 . · DOI
  7. M. D. Logsdon, and P. J. Eifel .FIGO stage IIIB squamous cell carcinoma of the uterine cervix: An analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy., Int. J. Radiat. Oncol. Biol. Phys, 43 :763 –775 .1999 . · DOI
  8. P. J. Eifel, High dose-rate brachytherapy for carcinoma of the cervix: High tech or high risk? Int. J. Radiat. Oncol. Biol. Phys, 24 :383 –386 .1992 . · DOI
  9. 10.1016/S0360-3016(99)00262-X · DOI
  10. 10.1006/gyno.1994.1215 · DOI
  11. F. Leborgne, J. H. Leborgne, R. Doldán, E. Zubizarreta, B. Ortega, J. Maisonneuve, E. Musetti, L. Hekimian, and J. Mezzera .Induction chemotherapy and radiotherapy of advanced cancer of the cervix: A pilot study and phase III randomized trial., Int. J. Radiat. Oncol. Biol. Phys, 37 :343 –350 .1997 . · DOI
  12. L. Souhami, R. Gil, S. Allan, P. C. Canary, C. M. Araújo, L. H. Pinto, and T. R. Silveiro .A randomized trial of chemotherapy followed by pelvic radiation therapy in Stage IIIB carcinoma of the cervix., Int. J. Radiat. Oncol. Biol. Phys, 9 :970 –997 .1991 . · DOI
  13. 10.1002/(SICI)1097-0142(19960601)77:11<2371::AID-CNCR28>3.0.CO;2-T · DOI
  14. M. H N. Tattersall, V. Larvidhaya, V. Vootiprux, A. Cheirsilpa, F. Wong, T. Azhar, H. P. Lee, S. Kang, A. Manalo, and M. S. Yen .Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer., Am. J. Clin. Oncol, 13 :444 –451 .1995 . · DOI
  15. 10.1046/j.1525-1438.1992.02050244.x · DOI
  16. 10.1006/gyno.1997.4812 · DOI
  17. 10.1016/S0889-8588(05)70091-5 · DOI
  18. S. El-Sayed, and N. Nelson .Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials., J. Clin. Oncol, 14 :838 –847 .1996 . · DOI
  19. A. J. Munro, An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer., Br. J. Cancer, 71 :83 –91 .1995 . · DOI
  20. 10.1016/1053-4296(92)90008-9 · DOI
  21. J. D. Cox, C. B. Scott, R. W. Byhardt, B. Emami, A. H. Russell, K. K. Fu, M. B. Parliament, R. Komaki, and L. E. Gaspar .Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): Analysis of Radiation Therapy Oncology Group (RTOG) trials., Int. J. Radiat. Oncol. Biol. Phys, 43 :505 –509 .1999 . · DOI
  22. C. M. Coppin, M. K. Gospodarowicz, K. James, I. F. Tannock, B. Zee, J. Carson, J. Pater, and L. D. Sullivan .Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group., J. Clin. Oncol, 14 :2901 –2907 .1996 . · DOI
  23. W. U. Shipley, K. A. Winter, D. S. Kaufman, W. R. Lee, N. M. Heney, W. R. Tester, B. J. Donnelly, P. M. Venner, C. A. Perez, and L. D. True .Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03., J. Clin. Oncol, 16 :3576 –3583 .1998 . · DOI
  24. 10.2307/3572022 · DOI
  25. 10.1002/1097-0142(197202)29:2<407::AID-CNCR2820290223>3.0.CO;2-T · DOI
  26. M. Piver, J. Barlow, V. Vongtama, and J. Webester .Hydroxyurea and radiation therapy in advanced cervical cancer., Am. J. Obstet. Gynecol, 120 :969 –972 .1974 . · DOI
  27. P. Carde, and F. Laval .Effect of cis-dichlorodiammine platinum II and X rays on mammalian cell survival., Int. J.Radiat. Oncol. Biol. Phys, 7 :929 –933 .1981 . · DOI
  28. R. F. Kallman, D. Rapacchietta, and M. S. Zaghloul .Schedule-dependent therapeutic gain from the combination of fractionated irradiation plus c-DDP and 5-FU or plus c-DDP and cyclophosphamide in C3H/Km mouse model systems., Int. J. Radiat. Oncol. Biol. Phys, 20 :227 –232 .1991 . · DOI
  29. J. Byfield, P. Calabro-Jones, I. Klisak, and F. Kulhanian .Pharmacologic requirements for obtaining sensitization of human tumor cellsin vitroto combined 5-fluorouracil or ftorafur and x-rays., Int. J. Radiat. Oncol. Biol. Phys, 8 :1923 –1933 .1982 . · DOI
  30. 10.1016/S1053-4296(97)80023-9 · DOI
  31. 10.1056/NEJM199408253310803 · DOI
  32. F. B. Stehman, B. N. Bundy, H. Keys, J. L. Currie, R. Mortel, and W. T. Creasman .A randomized trial of hydroxyurea versus misonidazole adjunct to radiation therapy in carcinoma of the cervix. A preliminary report of a Gynecologic Oncology Group study., Am. J. Obstet. Gynecol, 159 :87 –94 .1988 . · DOI
  33. S. Leibel, M. Bauer, T. Wasserman, V. Marcial, M. Rotman, N. Hornback, J. Cooper, B. Gillespie, E. Pakuris, and N. Conner .Radiotherapy with or without misonidazole for patients with stage IIIB or IVA squamous cell carcinoma of the uterine cervix: Preliminary report of a Radiation Therapy Oncology Group randomized trial., Int. J. Radiat. Oncol. Biol. Phys, 13 :541 –549 .1987 . · DOI
  34. J. Overgaard, S. M. Bentzen, P. Kolstad, K. Kjørstad, M. Davy, K. Bertelsen, M. Mantyla, B. Frankendal, A. Skryten, and I. Loftquist .Misonidazole combined with radiotherapy in the treatment of carcinoma of the uterine cervix., Int. J. Radiat. Oncol. Biol. Phys, 16 :1069 –1072 .1989 . · DOI
  35. F. B. Stehman, B. N. Bundy, G. Thomas, H. M. Keys, G. d'Ablaing III, W. C. Fowler, R. Mortel, and W. T. Creasman .Hydroxyurea versus misonidazole with radiation in cervical carcinoma: Long-term follow-up of a Gynecologic Oncology Group trial., J. Clin. Oncol, 11 :1523 –1528 .1993 . · DOI
  36. 10.1093/jnci/91.6.500a · DOI
  37. 10.1001/jama.274.5.387 · DOI
  38. 10.1016/0090-8258(89)90035-8 · DOI
  39. A. W. Chaney, P. J. Eifel, M. D. Logsdon, M. Morris, and J. T. Wharton .Mature results of a pilot study of pelvic radiotherapy with concurrent continuous infusion intra-arterial 5-FU for stage IIIB–IVA squamous cell carcinoma of the cervix., Int. J. Radiat. Oncol. Biol. Phys, 45 :113 –118 .1999 . · DOI
  40. 10.1006/gyno.1998.4990 · DOI
  41. 10.1016/0167-8140(95)01648-1 · DOI
  42. 10.1259/0007-1285-64-759-252 · DOI
  43. 10.1097/00000421-198910000-00015 · DOI
  44. E. Rakovitch, A. W. Fyles, M. Pintilie, and P. M. Leung .Role of mitomycin C in the development of late bowel toxicity following chemoradiation for locally advanced carcinoma of the cervix., Int. J. Radiat. Oncol. Biol. Phys, 38 :979 –987 .1997 . · DOI
  45. 10.1016/0090-8258(90)90089-4 · DOI

Cited by

Sorted by citations

Metadata

Authors
Eifel, P. J.
Affiliations
The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Eifel, Patricia J.
ORCID
Eifel, Patricia J.
Venue
Radiation Research
Publisher
Radiation Research Society
Published
2000-09
Volume
154
Issue
3
Pages
229-236
ISSN
  • 0033-7587 (ISSN-L)
  • 1938-5404
DOI
10.1667/0033-7587(2000)154[0229:cfcotc]2.0.co;2
OpenAlex
W2249828420
Cited by
38
References
0
Citations by year
2024: 1 · 2023: 1 · 2020: 1 · 2018: 1 · 2015: 1 · 2014: 2 · 2012: 2
FWCI
1.52
Type
journal article
Language
en
Open access
closed
Locations
  • Radiation Research (publishedVersion)
  • PubMed (publishedVersion)
  • BioOne Complete (BioOne) (submittedVersion)
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
Keywords
cervical cancer, chemoradiotherapy, concurrent chemoradiotherapy, neoadjuvant chemotherapy, cisplatin, locally advanced cervical cancer, locoregional recurrence, local control, survival
MeSH terms
Antineoplastic Combined Chemotherapy Protocols, Bleomycin, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Cisplatin, Combined Modality Therapy, Drug Administration Schedule, Female, Fluorouracil, Head and Neck Neoplasms, Humans, Hydroxyurea, Hysterectomy, Lung Neoplasms, Prospective Studies, Radiation Tolerance, Radiation-Sensitizing Agents, Vincristine, Survival Rate, Randomized Controlled Trials as Topic, Mitomycin, Treatment Outcome, Chemotherapy, Adjuvant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review